John R. Moore - 16 Jun 2022 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role: General Counsel
Signature: /s/ John R. Moore
Issuer symbol: EWTX
Transactions as of: 16 Jun 2022
Net transactions value: -$349,316
Form type: 4
Filing time: 21 Jun 2022, 18:50:53 UTC
Previous filing: 15 Jun 2022
Next filing: 07 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EWTX	Common Stock	Options Exercise	$28,413	+14,722	+491%	$1.93	17,722	16 Jun 2022	Direct	F1
transaction	EWTX	Common Stock	Sale	$90,805	-14,722	-83%	$6.17	3,000	16 Jun 2022	Direct	F2
transaction	EWTX	Common Stock	Options Exercise	$42,705	+22,127	+738%	$1.93	25,127	17 Jun 2022	Direct
transaction	EWTX	Common Stock	Sale	$146,434	-22,127	-88%	$6.62	3,000	17 Jun 2022	Direct	F3
transaction	EWTX	Common Stock	Options Exercise	$9,591	+13,508	+450%	$0.7100^*	16,508	21 Jun 2022	Direct
transaction	EWTX	Common Stock	Options Exercise	$33,910	+17,570	+106%	$1.93	34,078	21 Jun 2022	Direct
transaction	EWTX	Common Stock	Sale	$226,695	-31,078	-91%	$7.29	3,000	21 Jun 2022	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EWTX	Stock Option (Right to Buy)	Options Exercise	$0	-14,722	-7.5%	$0.000000	181,614	16 Jun 2022	Common Stock	14,722	$1.93	Direct	F5
transaction	EWTX	Stock Option (Right to Buy)	Options Exercise	$0	-22,127	-12%	$0.000000	159,487	17 Jun 2022	Common Stock	22,127	$1.93	Direct	F5
transaction	EWTX	Stock Option (Right to Buy)	Options Exercise	$0	-17,570	-11%	$0.000000	141,917	21 Jun 2022	Common Stock	17,570	$1.93	Direct	F5
transaction	EWTX	Stock Option (Right to Buy)	Options Exercise	$0	-13,508	-10%	$0.000000	121,562	21 Jun 2022	Common Stock	13,508	$0.7100	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022.
F2	The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.26, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.21 to $6.89, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.72 to $7.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5	1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date.
F6	1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.